2.36
1.72%
0.04
Handel nachbörslich:
2.38
0.02
+0.85%
Minerva Neurosciences Inc Aktie (NERV) Neueste Nachrichten
Minerva Neurosciences: Q3 Earnings Snapshot - San Francisco Chronicle
Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates - GlobeNewswire
Major Depressive Disorder Market Expected to Experience Major Growth by 2034, According to DelveInsight | Takeda, Otsuka Pharma, AbbVie, SAGE Therapeutics, Forest Laboratories, Axsome Therapeutics - The Globe and Mail
Cognitive Impairment Disorders Treatment A Game Changer for Global Finance Forecast-Eli Lilly and Company, AstraZeneca, – IndiaPolitics.com - IndiaPolitics.com
Japan Receptor Tyrosine Protein Kinase ERBB 4 Industry Size, Share, Price, Trends, Forecast (2024-2034) - IndiaPolitics.com
Minerva Neurosciences (NASDAQ:NERV) Share Price Passes Below 200-Day Moving Average – What’s Next? - Defense World
Schizophrenia Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Reviva Pharma, Minerva Neurosciences, Karuna Therapeutics, Acadia Pharma, Boehringer Ingelheim, Sunovion - Barchart
Neurological diseases index falls; Sarepta and Intra-Cellular report gains - BioWorld Online
Inari Medical director sells $1.83M in common stock - TipRanks
Intuitive Machines Shares Soar on NASA Pact for Near-Space Grid - Bloomberg
Intuitive Machines Stock Soars on New NASA Contract. This Is Big. - Barron's
Intuitive Machines Stock Is Soaring Wednesday: What's Going On? - Benzinga
Why Intuitive Machines Shares Are Trading Higher By Around 41%; Here Are 20 Stocks Moving Premarket - Benzinga
After-hours movers: Intuitive Machines, Casella Waste Systems, Galmed Pharma, Edgewise Therapeutics - Investing.com Australia
Minerva Neurosciences (NASDAQ:NERV) Receives New Coverage from Analysts at StockNews.com - Defense World
Rathbones Group PLC Increases Stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) - MarketBeat
INmune Bio stock dips on $13M securities offering - MSN
Minerva Neurosciences (NASDAQ:NERV) versus AC Immune (NASDAQ:ACIU) Head-To-Head Survey - Defense World
StockNews.com Begins Coverage on Minerva Neurosciences (NASDAQ:NERV) - Defense World
Rubertis Francesco De Net Worth (2024) - GuruFocus.com
Minerva Neurosciences (NASDAQ:NERV) Now Covered by Analysts at StockNews.com - Defense World
Research Analysts Issue Forecasts for Minerva Neurosciences, Inc.’s Q3 2024 Earnings (NASDAQ:NERV) - Defense World
Minerva Neurosciences (NASDAQ:NERV) Price Target Cut to $5.00 - Defense World
HC Wainwright Weighs in on Minerva Neurosciences, Inc.’s Q4 2024 Earnings (NASDAQ:NERV) - Defense World
Minerva Neurosciences: Q2 Earnings Snapshot - San Antonio Express-News
Minerva Neurosciences Reports Second Quarter 2024 Financial Results and Business Updates - GlobeNewswire
Minerva Neurosciences (NASDAQ:NERV) Now Covered by StockNews.com - Defense World
Minerva Neurosciences (NASDAQ:NERV) Earns Sell Rating from Analysts at StockNews.com - Defense World
Minerva Neurosciences (NASDAQ:NERV) Coverage Initiated at StockNews.com - Defense World
Minerva Neurosciences (NASDAQ:NERV) Share Price Crosses Below 200 Day Moving Average of $4.42 - Defense World
StockNews.com Initiates Coverage on Minerva Neurosciences (NASDAQ:NERV) - Defense World
Cognitive Behavioral Therapy for Insomnia Market Insights, Industry Outlook, Growing Trends with Top Key Players – MINERVA NEUROSCIENCES INC, CURRAX PHARMACEUTICALS LLC, Pfizer Inc., Sanofi, zydus cadila – TIMC - TIMC
Minerva Neurosciences (NASDAQ:NERV) Stock Price Passes Below 200-Day Moving Average of $4.54 - Defense World
Cartesian (RNAC) MG Study Meets Goals, Stock Down on Other Updates - Zacks Investment Research
Are Options Traders Betting on a Big Move in Minerva Neurosciences (NERV) Stock? - Yahoo Lifestyle UK
Design, Sarepta, Wave rise amid overall neurological index decline - BioWorld Online
Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates - Quantisnow
Minerva Neurosciences Announces Listing Transfer to Nasdaq Capital Market - Quantisnow
Minerva Neurosciences Reports Second Quarter 2021 Financial Results and Business Updates - Quantisnow
Minerva Neurosciences to Report Fiscal Year 2022 Financial Results and Business Updates on March 8, 2023 - Quantisnow
Minerva Neurosciences to Present at JMP Securities Life Sciences Conference - Quantisnow
Minerva Neurosciences and Royalty Pharma Announce Sale of Seltorexant Royalty for up to $155 Million - Quantisnow
Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business Updates - Quantisnow
Minerva Neurosciences to Report Second Quarter 2021 Financial Results and Business Updates on August 2, 2021 - Quantisnow
Minerva Neurosciences to Report Third Quarter 2021 Financial Results and Business Updates on November 8 - Quantisnow
Minerva Neurosciences to Report First Quarter 2021 Financial Results and Business Updates on May 12, 2021 - Quantisnow
Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business Updates - Quantisnow
Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of ... - Quantisnow
Minerva Neurosciences Announces Promotion of Geoff Race to President - Quantisnow
Implied Volatility Surging for Minerva Neurosciences (NERV) Stock Options - Yahoo New Zealand News
Minerva Neurosciences (NASDAQ:NERV) Share Price Crosses Above 50-Day Moving Average of $2.74 - Defense World
Minerva Neurosciences (NASDAQ:NERV) Research Coverage Started at StockNews.com - Defense World
Roche's Ocrevus Subcutaneous Gets European Commission Nod - Markets Insider
Roche's (RHHBY) Ocrevus Subcutaneous Gets European Commission Nod - Zacks Investment Research
Roche's (RHHBY) Ocrevus Subcutaneous Gets European Commission Nod - Yahoo Finance
Is the Options Market Predicting a Spike in Minerva Neurosciences (NERV) Stock? - Yahoo New Zealand News
Minerva Neurosciences (NASDAQ:NERV) Stock Price Passes Above Fifty Day Moving Average of $2.65 - Defense World
Minerva Neurosciences: 3Q Earnings Snapshot - Yahoo Movies UK
Here's Why Minerva Neurosciences (NERV) Could be Great Choice for a Bottom Fisher - Yahoo New Zealand News
Ultragenyx Posts New Data From Bone Disease Study - Markets Insider
Ultragenyx (RARE) to Seek Accelerated Nod for Rare Disease Drug - Yahoo Canada Finance
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):